MedTrace Logo

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

NCT00302536 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-02-09

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.

Conditions

  • Focal Glomerulosclerosis

Interventions

DRUG

Tacrolimus

Tacrolimus

Sponsors & Collaborators

  • Nanjing University School of Medicine

    lead OTHER

Principal Investigators

  • Zhi-hong Liu, M.D. · Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2010-05-31
Completion
2010-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302536 on ClinicalTrials.gov